June 1, 2018 — Chicago, IL


Event: Immuno-Oncology BD&L and Investment Forum

Panel Session: Deal-making and M&A

Co-chairs:
Jonathan Kfoury, Managing Director, L.E.K. Consulting
Michael Margolis, Co-Head of Healthcare Investment Banking, Oppenheimer & Co., Inc.

Panelists:

  • Andrew Hass, Senior Advisor, Oncology External Innovation, Eli Lilly & Co.
  • Chris Sheldon, Head of Oncology Search & Evaluation, AstraZeneca
  • Guillaume Vignon, Senior Vice President Business Development, BeiGene Ltd.
  • Matthias Müllenbeck, Director Global Oncology L&BD, Merck KGaA

Date/Location:

Friday, June 1, 2018      
Waldorf Astoria Chicago Hotel
Chicago, IL

Time: 9:00 a.m. — 9:40 a.m.


About Jonathan Kfoury     

Jonathan Kfoury is a Managing Director and Partner in L.E.K. Consulting’s San Francisco office, focused on biopharmaceuticals, medical technology and life sciences. He joined the firm in 2006, and since that time has led an extensive set of engagements with global biopharmaceutical, medical technology and diagnostic clients across human health, animal health and agribusiness markets. Jonathan advises clients on commercial strategy and life-cycle management for in-line products, market access and commercialization planning for pipeline assets, and growth/partnering strategy. With an operating background in both clinical and business development at specialty biopharmaceutical companies, Jonathan brings a hands-on understanding of internal decision-making needs to his advisory work with clients.

In addition to significant experience in immunology, oncology, men’s/women’s health and CNS/pain management, Jonathan’s interests include growth strategy for antibiotics and infectious-diseases, biosimilars and digital health opportunities.

In addition to global management training at INSEAD, Jonathan earned an S.M. in Health Policy & Management from Harvard University, and graduated from Trinity College with a Bachelor of Science degree in Neuroscience.
 
2018 Immuno-Oncology BD&L and Investment Forum

Taking place on the first day of the American Society of Clinical Oncology (ASCO) annual meeting, the Fourth Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. This year, there will be approximately 200 delegates and over 20 presentations by listed and private biotechnology companies seeking licensing and investment.

About L.E.K. Consulting

L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries — including the largest private- and public-sector organizations, private equity firms, and emerging entrepreneurial businesses. Founded in 1983, L.E.K. employs more than 1,200 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.